Nuvalent (NUVL) Projected to Post Earnings on Thursday

Key Points

• Nuvalent is set to release its Q2 2025 earnings on Thursday, August 14th, with analysts expecting a loss of ($1.27) per share, following a recent quarter where it reported ($1.18) EPS, missing estimates.
• The company's stock has been given multiple buy ratings from analysts, with an average price target of $119.60 and upgrades from institutions including Goldman Sachs and Leerink Partners.
• Insider trading activity included significant sales by CEO James Richard Porter and insider Henry E. Pelish, with insiders collectively selling 85,645 shares in the last ninety days.

Nuvalent (NASDAQ:NUVL - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Nuvalent to post earnings of ($1.27) per share for the quarter.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.14) by ($0.04). During the same period last year, the business earned ($0.69) earnings per share. On average, analysts expect Nuvalent to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Nuvalent Stock Performance

Shares of NASDAQ NUVL opened at $77.23 on Thursday. The stock's 50-day simple moving average is $79.03 and its 200-day simple moving average is $76.27. The firm has a market capitalization of $5.55 billion, a PE ratio of -17.59 and a beta of 1.30. Nuvalent has a fifty-two week low of $55.53 and a fifty-two week high of $113.51.

Wall Street Analyst Weigh In

A number of analysts have weighed in on NUVL shares. The Goldman Sachs Group raised shares of Nuvalent to a "strong-buy" rating in a report on Monday, June 30th. Leerink Partners lifted their price target on shares of Nuvalent from $125.00 to $140.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 24th. Wedbush reissued an "outperform" rating and issued a $115.00 price target on shares of Nuvalent in a research report on Monday, July 21st. Robert W. Baird upped their price objective on shares of Nuvalent from $105.00 to $112.00 and gave the company an "outperform" rating in a research note on Wednesday, June 25th. Finally, HC Wainwright reiterated a "buy" rating and set a $130.00 target price (up previously from $110.00) on shares of Nuvalent in a research report on Tuesday, June 24th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $119.60.

Insider Buying and Selling at Nuvalent

In other news, insider Henry E. Pelish sold 8,630 shares of the company's stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $79.87, for a total transaction of $689,278.10. Following the completion of the sale, the insider owned 63,101 shares in the company, valued at $5,039,876.87. This represents a 12.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO James Richard Porter sold 27,000 shares of the business's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $82.27, for a total transaction of $2,221,290.00. Following the completion of the transaction, the chief executive officer directly owned 249,062 shares in the company, valued at $20,490,330.74. This represents a 9.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 85,645 shares of company stock worth $7,007,857. 10.20% of the stock is currently owned by insiders.

Institutional Trading of Nuvalent

A number of institutional investors have recently modified their holdings of the business. AQR Capital Management LLC grew its position in Nuvalent by 64.8% during the first quarter. AQR Capital Management LLC now owns 9,874 shares of the company's stock worth $700,000 after buying an additional 3,881 shares during the period. Intech Investment Management LLC boosted its stake in shares of Nuvalent by 28.7% during the 1st quarter. Intech Investment Management LLC now owns 19,262 shares of the company's stock worth $1,366,000 after acquiring an additional 4,293 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Nuvalent by 8.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company's stock worth $10,634,000 after acquiring an additional 12,123 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in Nuvalent by 54.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company's stock valued at $32,171,000 after purchasing an additional 159,873 shares in the last quarter. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

About Nuvalent

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.